42 related articles for article (PubMed ID: 11248291)
1. Analysis of the activated partial thromboplastin time test using mathematical modeling.
Kogan AE; Kardakov DV; Khanin MA
Thromb Res; 2001 Feb; 101(4):299-310. PubMed ID: 11248291
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic uses of the activated partial thromboplastin time and prothrombin time.
Suchman AL; Griner PF
Ann Intern Med; 1986 Jun; 104(6):810-6. PubMed ID: 3706933
[TBL] [Abstract][Full Text] [Related]
3. [Investigation of coagulation time: PT and APTT].
Ramakers C; van der Heul C; van Wijk EM
Ned Tijdschr Geneeskd; 2012; 156(0):A3985. PubMed ID: 22917038
[TBL] [Abstract][Full Text] [Related]
4. Activated partial thromboplastin time.
Ignjatovic V
Methods Mol Biol; 2013; 992():111-20. PubMed ID: 23546708
[TBL] [Abstract][Full Text] [Related]
5. Assessment of prothrombin time, activated partial thromboplastin time, and fibrinogen concentration on equine plasma samples following different storage conditions.
Casella S; Giannetto C; Fazio F; Giudice E; Piccione G
J Vet Diagn Invest; 2009 Sep; 21(5):674-8. PubMed ID: 19737763
[TBL] [Abstract][Full Text] [Related]
6. The molecular lesion of hereditary spherocytosis (HS): a continuing enigma.
Valentine WN
Blood; 1977 Feb; 49(2):241-5. PubMed ID: 831876
[No Abstract] [Full Text] [Related]
7. Mathematical model for the blood coagulation prothrombin time test.
Khanin MA; Rakov DV; Kogan AE
Thromb Res; 1998 Mar; 89(5):227-32. PubMed ID: 9645916
[TBL] [Abstract][Full Text] [Related]
8. Critical evaluation of kinetic schemes for coagulation.
Ranc A; Bru S; Mendez S; Giansily-Blaizot M; Nicoud F; Méndez Rojano R
PLoS One; 2023; 18(8):e0290531. PubMed ID: 37639392
[TBL] [Abstract][Full Text] [Related]
9. A Review of Quantitative Systems Pharmacology Models of the Coagulation Cascade: Opportunities for Improved Usability.
Chung D; Bakshi S; van der Graaf PH
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986779
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312).
Pawaskar D; Chen X; Glassman F; May F; Roberts A; Biondo M; McKenzie A; Nolte MW; Jusko WJ; Tortorici M
Clin Transl Sci; 2022 Mar; 15(3):709-720. PubMed ID: 34811931
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy.
Hartmann S; Biliouris K; Lesko LJ; Nowak-Göttl U; Trame MN
Front Pharmacol; 2020; 11():1041. PubMed ID: 32765265
[TBL] [Abstract][Full Text] [Related]
12. Identification of disease states associated with coagulopathy in trauma.
Zhang Y; Wu TB; Daigle BJ; Cohen M; Petzold L
BMC Med Inform Decis Mak; 2016 Sep; 16(1):124. PubMed ID: 27658851
[TBL] [Abstract][Full Text] [Related]
13. A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics.
Zhou X; Huntjens D; Gilissen R
CPT Pharmacometrics Syst Pharmacol; 2015 Nov; 4(11):650-9. PubMed ID: 26783501
[TBL] [Abstract][Full Text] [Related]
14. Using a Systems Pharmacology Model of the Blood Coagulation Network to Predict the Effects of Various Therapies on Biomarkers.
Nayak S; Lee D; Patel-Hett S; Pittman DD; Martin SW; Heatherington AC; Vicini P; Hua F
CPT Pharmacometrics Syst Pharmacol; 2015 Jul; 4(7):396-405. PubMed ID: 26312163
[TBL] [Abstract][Full Text] [Related]
15. Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor.
Burghaus R; Coboeken K; Gaub T; Niederalt C; Sensse A; Siegmund HU; Weiss W; Mueck W; Tanigawa T; Lippert J
Front Physiol; 2014; 5():417. PubMed ID: 25426077
[TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin.
Gulati A; Faed JM; Isbister GK; Duffull SB
Pharm Res; 2012 Jan; 29(1):225-35. PubMed ID: 21822767
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.
Burghaus R; Coboeken K; Gaub T; Kuepfer L; Sensse A; Siegmund HU; Weiss W; Mueck W; Lippert J
PLoS One; 2011 Apr; 6(4):e17626. PubMed ID: 21526168
[TBL] [Abstract][Full Text] [Related]
18. Confinement regulates complex biochemical networks: initiation of blood clotting by "diffusion acting".
Shen F; Pompano RR; Kastrup CJ; Ismagilov RF
Biophys J; 2009 Oct; 97(8):2137-45. PubMed ID: 19843446
[TBL] [Abstract][Full Text] [Related]
19. Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa.
Wu W; Sinha D; Shikov S; Yip CK; Walz T; Billings PC; Lear JD; Walsh PN
J Biol Chem; 2008 Jul; 283(27):18655-64. PubMed ID: 18441012
[TBL] [Abstract][Full Text] [Related]
20. Blood coagulation dynamics under the conditions of Hageman factor deficiency: a mathematical model.
Obraztsov IF; Kuz'min VM; Khanin MA
Dokl Biochem Biophys; 2002; 386():248-50. PubMed ID: 12469501
[No Abstract] [Full Text] [Related]
[Next] [New Search]
